Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Lymphoma 539Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Lymphoma, Non-Hodgkin 435Lymphoma, Follicular 403Leukemia, Lymphocytic, Chronic, B-Cell 388Lymphoma, Large B-Cell, Diffuse 385Lymphoma, B-Cell 246Lymphoma, Mantle-Cell 222Hodgkin Disease 207Recurrence 204Leukemia, Myeloid, Acute 197Leukemia 191Multiple Myeloma 184Burkitt Lymphoma 181Lymphoma, B-Cell, Marginal Zone 170Neoplasms 151Myelodysplastic Syndromes 132Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 85Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 81Lymphoma, T-Cell, Cutaneous 66Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 54Breast Neoplasms 54Myeloproliferative Disorders 50Leukemia, B-Cell 50Lymphoproliferative Disorders 47

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Mesothelial × Lymphoid × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡